 SAN DIEGO, Sept. 08, 2021 GLOBE NEWSWIRE -- Longboard Pharmaceuticals, Inc. Nasdaq: LBPH, a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, announced today that the Company successfully completed the multiple ascending dose MAD portion of a Phase 1 clinical trial to assess the safety, tolerability, pharmacokinetics PK and pharmacodynamics PD of escalating doses of LP352, an oral, centrally acting, next-generation 5-HT2c receptor superagonist, in healthy volunteers. Longboard plans to advance LP352 into a Phase 1b2a efficacy trial in adult participants with DEEs in the first quarter of 2022 in study sites across the United States. 